| Trial ID: | L7034 |
| Source ID: | NCT00729898
|
| Associated Drug: |
Biphasic Insulin Aspart 30
|
| Title: |
Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: biphasic insulin aspart 30
|
| Outcome Measures: |
Primary: Incidence of serious adverse drug reactions, including major hypoglycaemic events, after 12 and 26 weeks | Secondary: Number of all hypoglycaemic events, in the 4 weeks preceding visit, at 12 weeks and the final visit at 26 weeks|Number of all adverse drug reactions, after 12 and 26 weeks|HbA1c, at 12 and 26 weeks|Variability in fasting plasma glucose (FPG) values and average FPG levels, at visits at 12 and 26 weeks|Weight changes, at visits at 12 and 26 weeks
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
243
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2008-03
|
| Completion Date: |
2010-09
|
| Results First Posted: |
|
| Last Update Posted: |
2016-10-31
|
| Locations: |
Novo Nordisk Investigational Site, Rud, 1309, Norway|Novo Nordisk Investigational Site, Farsta, 123 47, Sweden
|
| URL: |
https://clinicaltrials.gov/show/NCT00729898
|
